{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:24:46Z","timestamp":1792815886394,"version":"4.5.0"},"reference-count":100,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"Progetto Ricerca Finalizzata","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/14656566.2024.2333376","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T22:00:21Z","timestamp":1710885621000},"page":"421-434","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Selinexor in multiple myeloma"],"prefix":"10.1080","volume":"25","author":[{"given":"Enrica Antonia","family":"Martino","sequence":"first","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Labanca","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Olivito","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Zimbo","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"},{"name":"UOC Laboratorio Analisi Cliniche, Biomolecolari e Genetica, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Torricelli","sequence":"additional","affiliation":[{"name":"Laboratorio di Ricerca Traslazionale Azienda USL-IRCSS Reggio Emilia, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Scientific Directorate IRCCS of Reggio Emilia, I-42123 Reggio Emilia, EmiliaRomagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"},{"name":"Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14789450.2018.1543595"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1065250"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3035"},{"issue":"9","key":"e_1_3_4_7_1","first-page":"846","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza S","year":"2017","unstructured":"Raza S, Safyan RA, Lentzsch S. Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer Drug Targets. 2017;17(9):846\u2013857.","journal-title":"Curr Cancer Drug Targets"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1274973"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000334"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2193289"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2145882"},{"issue":"1","key":"e_1_3_4_12_1","first-page":"245","article-title":"Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials","volume":"109","author":"Gentile M","year":"2024","unstructured":"Gentile M, Vigna E, Palmieri S, et al. Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials. Haematologica. 2024 Jan 1;109(1):245\u2013255.","journal-title":"Haematologica"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3031"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.241513"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21771"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14121"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2218543"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02515"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174320"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29070355"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00733-2"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0078-0"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e12-01-0045"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.03.002"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.003"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1339"},{"issue":"20","key":"e_1_3_4_30_1","first-page":"5747","article-title":"Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroids and xenograft tumors","volume":"60","author":"Oloumi A","year":"2000","unstructured":"Oloumi A, MacPhail SH, Johnston PJ, et al. Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 2000 Oct 15;60(20):5747\u20135753.","journal-title":"Cancer Res"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2012.07.007"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0085-1"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986708786242859"},{"key":"e_1_3_4_34_1","unstructured":"Selinexor NDA [Internet]. 2024 Jan 6 [cited 2024 Jan 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212306Orig1s000MultidisciplineR.pdf"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25368"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12428"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3949"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750174"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6346"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01016-y"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750158"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04258-6"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-797886"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5207"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129038"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.120"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02305-4"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858852"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970448.14708.34"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26261"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.08.018"},{"issue":"1","key":"e_1_3_4_54_1","first-page":"1338","article-title":"A phase II study of selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory multiple myeloma: the SELVEDEX trial","volume":"2","author":"Broijl A","year":"2018","unstructured":"Broijl A, Asselbergs EL, Minnena MC, et al. A phase II study of selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory multiple myeloma: the SELVEDEX trial. Hemasphere. 2018;2(Supplement 1):1338.","journal-title":"Hemasphere"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01608-2"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158011"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15969"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13937"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.12.013"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.084"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148759"},{"key":"e_1_3_4_62_1","first-page":"56","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"2","author":"Gasparetto C","year":"2021","unstructured":"Gasparetto C, Lentzsch S, Schiller G, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2021;2:56\u201365","journal-title":"Eur J Haematol"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284089"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186220"},{"key":"e_1_3_4_65_1","first-page":"3095","article-title":"Phase I\/II study of liposomal doxorubicin (DOX) in combination with selinexor (SEL) and dexamethasone (DEX) for relapsed and refractory multiple myeloma (RRMM)","volume":"130","author":"Baz R","year":"2017","unstructured":"Baz R, Zonder JA, Shain KH, et al. Phase I\/II study of liposomal doxorubicin (DOX) in combination with selinexor (SEL) and dexamethasone (DEX) for relapsed and refractory multiple myeloma (RRMM). Blood. 2017;130:3095.","journal-title":"Blood"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00315-2"},{"key":"e_1_3_4_67_1","first-page":"626","article-title":"Effectiveness and safety of selinexor-based regimens in the treatment of relapsed and refractory multiple myeloma: a multicenter real-world study from China","volume":"35","author":"Lifen K","year":"2022","unstructured":"Lifen K, Baijun F, Wenming C, et al. Effectiveness and safety of selinexor-based regimens in the treatment of relapsed and refractory multiple myeloma: a multicenter real-world study from China. J Clin Hematol. 2022;35:626\u2013632.","journal-title":"J Clin Hematol"},{"issue":"2","key":"e_1_3_4_68_1","first-page":"224","article-title":"Single-center experience of selinexor-based combination therapies for relapsed multiple myeloma","volume":"23","author":"Ahmed N","year":"2023","unstructured":"Ahmed N, Wan S, Biran N, et al. Single-center experience of selinexor-based combination therapies for relapsed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(Supplement 2):224.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.07.013"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131321"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16550"},{"issue":"2","key":"e_1_3_4_72_1","first-page":"1546209","article-title":"Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment","volume":"23","author":"Baljevic M","year":"2023","unstructured":"Baljevic M, Moreau P, Tuchman P, et al. Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. Clin Lymphoma Myeloma Leuk. 2023;23(Supplement 2):1546209.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11995"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1790-z"},{"issue":"2","key":"e_1_3_4_75_1","first-page":"396","article-title":"Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed\/refractory multiple myeloma - P-396","volume":"23","author":"Kang Y","year":"2023","unstructured":"Kang Y, Neff J, Gasparotto C. Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed\/refractory multiple myeloma - P-396. Clin Lymphoma Myeloma Leuk. 2023;23(Supplement 2):396.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00147"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114305"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062504"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185169"},{"key":"e_1_3_4_80_1","unstructured":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM) Seli and Bortezomib + LDD in Triple-class Refractory MM and Seli and Pomalidomide + LDD in Relapsed Refractory MM. https:\/\/clinicaltrials.gov\/study\/NCT04414475"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0756-6"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-752840"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07321.x"},{"key":"e_1_3_4_84_1","first-page":"65","article-title":"Lymphoma expert committee of chinese society of clinical oncology. Principles for clinical use of selinexor in hematological system diseases (2022 edition)","volume":"32","author":"Leukemia Expert Committee of Chinese Society of Clinical Oncology","year":"2023","unstructured":"Leukemia Expert Committee of Chinese Society of Clinical Oncology. Lymphoma expert committee of chinese society of clinical oncology. Principles for clinical use of selinexor in hematological system diseases (2022 edition). J Leuk Lymphoma. 2023;32:65\u201373.","journal-title":"J Leuk Lymphoma"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.12.026"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.014"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.06.007"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0231"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.11.012"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2225"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13859"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.06.001"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01071-9"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184949"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.145"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1818.1818"},{"key":"e_1_3_4_97_1","first-page":"3134","article-title":"Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with refractory multiple myeloma","volume":"130","author":"Cornell RF","year":"2017","unstructured":"Cornell RF, Rossi AC, Baz R, et al. Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with refractory multiple myeloma. Blood. 2017;130:3134.","journal-title":"Blood"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148835"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00662-0"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.572"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180736"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2333376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:26:37Z","timestamp":1727180797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2333376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/14656566.2024.2333376"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2333376","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}